Company intelligence / Profile preview
Rophibio
Cheongwon-gun, Chungcheongbuk-do, South Korearophibio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Rophibio has an active pipeline with a focus on developing biosimilars for global markets. Its lead program is an aflibercept biosimilar in Phase 3 trials for age-related macular degeneration. Other programs include preclinical-stage dulaglutide and pembrolizumab biosimilars. The company leverages proprietary platforms for cell line development and genetic/cell-based drug technologies.
- Therapeutic areas
- ImmunologyOncologyEndocrinologyOphthalmology
- Modalities
- Monoclonal antibodyFusion proteinFc fusion proteinGene therapyStem cell therapy (platform)Protein (biologic)Small molecule (biosimilars to small molecule drugs)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Avantor – collaboration on pembrolizumab (“Keytruda”) biosimilar raw materials/process support
Beyond the preview
Go deeper on Rophibio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rophibio.